• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home The Classics Cardiology Classics

The HOPE trial: Ramipril significantly reduces cardiovascular events in high-risk patients with normal ejection fractions [Classics Series]

byAimme Li, MDandAndrew Cheung, MD MBA
February 25, 2014
in Cardiology Classics, The Classics
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image: CC/L. academia

1. Ramipril significantly reduces cardiovascular events including MI, stroke and death in high risk-patients in the absence of left ventricular dysfunction

Original Date of Publication: January 20, 2000

Study Rundown: The HOPE trial was the first to provide evidence for the potential benefit of angiotensin-converting-enzyme inhibitors (ACE-Is) for vascular protection in preventing adverse cardiac outcomes among a broad range of high-risk patients with normal ejection fractions. After its publication, there was some criticism that the blood pressure lowering effect of ramipril may have accounted for the improved cardiac outcomes, as opposed to the medication itself. However, most patients did not have baseline hypertension in this study and the difference in blood pressure between the two groups was very small.

Even in the absence of reduced ejection fraction or high blood pressure, the addition of ramipril for high-risk patients at least 55 years of age may be considered for protection against adverse cardiovascular outcomes and death.

Click to read study in the NEJM (New England Journal of Medicine)

EvidencePulse™by 2 Minute Medicine®

How does HOPE apply to your patient?

Describe your patient and EvidencePulse weighs this trial against later evidence and current guidelines, with citations.

Ask EvidencePulse

For a fuller review of the evidence, Deep research is a core feature of 2MM Max.

Primer: Prior to the publication of the HOPE trial, the benefit of ACE-Is had been well established in improving long-term outcomes in patients with heart failure associated with reduced left ventricular ejection fraction. There was also evidence for the value of these medications in controlling blood pressure, particularly in diabetic patients in the presence of microalbuminuria. At the time, however, there was limited evidence as to whether ACE-Is provided any cardiovascular protection in the absence of left ventricular dysfunction. That is, there was uncertainty as to whether the blockade of the renin-angiotensin system offers any inherent benefit in improving cardiac outcomes in high-risk populations, independent of its effect on blood pressure or preventing the progression of systolic heart failure.

The HOPE trial was published in The New England Journal of Medicine in 2000. This landmark randomized control study looked at the effect of ramipril on major cardiovascular events in high-risk patients over 55 years old with normal ejection fractions.

Relevant Reading:

  1. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386):782-788.
  2. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068.
  3. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355(9200):253-259.

In-Depth [randomized, control study]: This large, double-blind, randomized control study included 9,541 patients from 281 centers internationally. Patients with known low ejection fraction (EF<40%), history of heart failure or who were already on a ACE-inhibitor were excluded from this study. Patients were randomized to either receive 1) placebo or 2) ramipril titrated up to 10mg daily. Primary outcomes were myocardial infarction, stroke, or death from cardiovascular causes. The trial lasted a total of 5 years. The ramipril group demonstrated significantly reduced cardiovascular outcomes (i.e., MI, stroke, death) compared to the placebo group. This finding held true among a broad range of patients in this study: subgroup analysis showed that the benefit of ramipril was consistent despite sex, age, cardiac risk factors, presence of diabetes, evidence of cardiovascular disease, baseline blood pressure, or evidence of microalbuminuria. The most common adverse effect of ramipril was cough.

Trials since this one

What later trials found on the same question.

  1. 2005

    CLARITY In The Classics

    The early addition of clopidogrel significantly reduced the incidence of infarct-related arterial re-occlusion within 30 days following myocardial infarction

  2. 2005

    COMMIT In The Classics

    Adding early metoprolol does not further decrease the risk of death post-MI compared to conventional fibrinolytic therapy alone.

10 more since 2000

2MM+ See every trial since HOPE

2MM+ shows the full timeline of later trials on this question, with what each one found, and lets you save trials to reading lists for rounds, journal club and boards.

See 2MM+ plans Sign in

Citation: Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53. doi: 10.1056/nejm200001203420301. PMID: 10639539.

© 2012 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine

Tags: HOPE Trialramipril

New landmark trials, every weekday

The free 2 Minute Medicine Daily Brief: practice-changing studies summarized by physicians, in your inbox.

Your subscription opens securely in a new tab.

More Cardiology Classics

Previous Post

Decreasing incidence of heart failure observed in Ontario, Canada

Next Post

Increased blood pressure variability during the subacute stage of ischemic stroke is associated with worsened functional outcomes at 3 months

Next Post

Increased blood pressure variability during the subacute stage of ischemic stroke is associated with worsened functional outcomes at 3 months

A phase I trial of neural stem cells in a disease of myelination shows promising results

Intermittent and continuous antiretroviral therapies are equivalent in the treatment of acute HIV-1 infection

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-term use of mometasone (Asmanex) in adults with sickle cell disease without formal diagnosis of asthma may worsen disease activity
  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.